Keryx Biopharmaceuticals, Inc.
KERX (the "Company") today announced that Phase 2 clinical results of
Zerenex™ (ferric citrate coordination complex) in non-dialysis dependent
chronic kidney disease (NDD-CKD) patients with elevated serum phosphorus and
iron deficiency anemia has been selected as a Late Breaking oral presentation
at the National Kidney Foundation 2014 Spring Clinical Meeting, taking place
April 22-26, 2014 in Las Vegas, NV. This presentation, entitled "Zerenex™
(Ferric Citrate) for the Treatment of Iron-Deficiency Anemia and Reduction of
Serum Phosphate in Non-Dialysis Dependent CKD," will be made during the Late
Breaking Session on Friday, April 25, 2014, from 9:30am - 11:00am PDT, by Dr.
Geoffrey Block, Director of Clinical Research at Denver Nephrology and
Co-Chairman for this study.
In addition to the late-breaking oral presentation, the following four
abstracts have also been selected for poster presentation during the meeting.
* "Phosphorus Binding with Ferric Citrate is Associated with Fewer
Hospitalizations and Reduced Hospitalization Costs," R. Rodby, poster
number 422;
* "Economic Impact of Ferric Citrate Versus Standard of Care for
Hemodialysis Patients," S. Brunelli, poster number 156;
* "Phosphorus Binding with Ferric Citrate Reduces Erythropoiesis-Stimulating
Agent (ESA) and IV Iron Usage and Cost in Patients with ESRD," R. Rodby,
poster number 415; and
* "Oral Ferric Citrate Eliminates the Need for Intravenous (IV) Iron in
Dialysis Patients," M. Sika, poster number 79.
Posters will be presented in the Exhibit Hall on Wednesday, April 23, from
6:00pm-7:30pm PDT.
Each of the above mentioned abstracts are currently available on the National
Kidney Foundation's website:
http://www.kidney.org/news/meetings/clinical/abstract/index.cfm.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in